124 related articles for article (PubMed ID: 26472477)
41. Discontinued drug therapies to treat diabetes in 2015.
Hedrington MS; Davis SN
Expert Opin Investig Drugs; 2017 Feb; 26(2):219-225. PubMed ID: 27997806
[TBL] [Abstract][Full Text] [Related]
42. NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned.
Keppel Hesselink JM
Drug Dev Res; 2017 Mar; 78(2):75-80. PubMed ID: 28195646
[TBL] [Abstract][Full Text] [Related]
43. Discontinued drugs in 2005: cardiovascular drugs.
Suckling K
Expert Opin Investig Drugs; 2006 Nov; 15(11):1299-308. PubMed ID: 17040192
[TBL] [Abstract][Full Text] [Related]
44. Advances and challenges in neuropathic pain: a narrative review and future directions.
Attal N; Bouhassira D; Colvin L
Br J Anaesth; 2023 Jul; 131(1):79-92. PubMed ID: 37210279
[TBL] [Abstract][Full Text] [Related]
45. The multiple challenges of neuropathic pain.
Bouhassira D; Attal N
Neurosci Lett; 2019 May; 702():6-10. PubMed ID: 30503925
[TBL] [Abstract][Full Text] [Related]
46. The need for fundamental reforms in the pain research field to develop innovative drugs.
Nagakura Y
Expert Opin Drug Discov; 2017 Jan; 12(1):39-46. PubMed ID: 27838932
[TBL] [Abstract][Full Text] [Related]
47. The design of multitarget ligands for chronic and neuropathic pain.
Dvoracsko S; Stefanucci A; Novellino E; Mollica A
Future Med Chem; 2015; 7(18):2469-83. PubMed ID: 26652942
[TBL] [Abstract][Full Text] [Related]
48. Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018.
Li T; Jiang S; Ni B; Cui Q; Liu Q; Zhao H
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547243
[TBL] [Abstract][Full Text] [Related]
49. Estimates of Probabilities of Successful Development of Pain Medications: An Analysis of Pharmaceutical Clinical Development Programs from 2000 to 2020.
Maher DP; Wong CH; Siah KW; Lo AW
Anesthesiology; 2022 Aug; 137(2):243-251. PubMed ID: 35504001
[TBL] [Abstract][Full Text] [Related]
50. Designing innovative therapies for neuropathic pain: pros and cons of target-based drug discovery.
Inglese J
J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2(Suppl 2):S6-9. PubMed ID: 25269741
[No Abstract] [Full Text] [Related]
51. A Review of the Clinical and Therapeutic Implications of Neuropathic Pain.
Balzani E; Fanelli A; Malafoglia V; Tenti M; Ilari S; Corraro A; Muscoli C; Raffaeli W
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572423
[TBL] [Abstract][Full Text] [Related]
52. Multi-functional Chimeric Peptides: The More the Merrier.
Singh A; Srivastava V
Protein Pept Lett; 2018; 25(12):1090-1100. PubMed ID: 30457042
[TBL] [Abstract][Full Text] [Related]
53. Novel Drug Delivery Systems.
Lou L
Curr Rev Pain; 1999; 3(5):411-416. PubMed ID: 10998698
[TBL] [Abstract][Full Text] [Related]
54. Introduction to the PAIN supplement on neuropathic pain.
Hietaharju A; Finnerup NB
Pain; 2018 Mar; 159(3):568. PubMed ID: 29447135
[No Abstract] [Full Text] [Related]
55. The obligation to publishing negative outcome data from neuropathic pain clinical trials.
Sindrup SH
Scand J Pain; 2013 Apr; 4(2):75-76. PubMed ID: 29913905
[No Abstract] [Full Text] [Related]
56. Editorial: Translational research in neuropathic pain: Current status and future directions.
Karri J; Nagpal AS; Li S
Front Pain Res (Lausanne); 2022; 3():1024013. PubMed ID: 36158702
[No Abstract] [Full Text] [Related]
57. Transition of COVID-19 to endemic phase and emergence of COVID-19 related neuropathic pain.
Choi JI
Korean J Pain; 2022 Jul; 35(3):237-239. PubMed ID: 35768978
[No Abstract] [Full Text] [Related]
58. Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade.
Xu ZZ; Kim YH; Bang S; Zhang Y; Berta T; Wang F; Oh SB; Ji RR
Nat Med; 2015 Nov; 21(11):1326-31. PubMed ID: 26479925
[TBL] [Abstract][Full Text] [Related]
59. Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ.
Krukowski K; Nijboer CH; Huo X; Kavelaars A; Heijnen CJ
Pain; 2015 Nov; 156(11):2184-2192. PubMed ID: 26473292
[TBL] [Abstract][Full Text] [Related]
60. Analgesic effects of mambalgin peptide inhibitors of acid-sensing ion channels in inflammatory and neuropathic pain.
Diochot S; Alloui A; Rodrigues P; Dauvois M; Friend V; Aissouni Y; Eschalier A; Lingueglia E; Baron A
Pain; 2016 Mar; 157(3):552-559. PubMed ID: 26492527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
